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Abstract
We recently reported that two artemisinin-derived dimers (dimer primary alcohol 606 and dimer sulfone 4-carbamate 832-4)
are significantly more potent in inhibiting human cytomegalovirus (CMV) replication than artemisinin-derived monomers. In
our continued evaluation of the activities of artemisinins in CMV inhibition, twelve artemisinin-derived dimers and five
artemisinin-derived monomers were used. Dimers as a group were found to be potent inhibitors of CMV replication.
Comparison of CMV inhibition and the slope parameter of dimers and monomers suggest that dimers are distinct in their
anti-CMV activities. A deoxy dimer (574), lacking the endoperoxide bridge, did not have any effect on CMV replication,
suggesting a role for the endoperoxide bridge in CMV inhibition. Differences in anti-CMV activity were observed among
three structural analogs of dimer sulfone 4-carbamate 832-4 indicating that the exact placement and oxidation state of the
sulfur atom may contribute to its anti-CMV activity. Of all tested dimers, artemisinin-derived diphenyl phosphate dimer 838
proved to be the most potent inhibitor of CMV replication, with a selectivity index of approximately 1500, compared to our
previously reported dimer sulfone 4-carbamate 832-4 with a selectivity index of about 900. Diphenyl phosphate dimer 838
was highly active against a Ganciclovir-resistant CMV strain and was also the most active dimer in inhibition of cancer cell
growth. Thus, diphenyl phosphate dimer 838 may represent a lead for development of a highly potent and safe anti-CMV
compound.
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Introduction
Infection with CMV, a member of the herpesvirus family, is
common in humans. Seroprevalence rates increase with age,
reaching 90% in individuals older than 80 years [1]. The virus
establishes lifelong persistent infection, which usually remains
asymptomatic. In immunocompromised hosts such as transplant
recipients and patients with AIDS, CMV infection is associated
with significant morbidity and mortality [2,3]. CMV is also the
most common congenitally-acquired infection causing mental
retardation and deafness in congenitally-infected children [4].
Recently, the detection of CMV in immunocompetent individuals
has been linked with outcomes of several syndromes including
sepsis, pulmonary complications in patients in intensive care-units,
and in a brain tumor, glioblastoma multiforme [5–7]. Although
the direct role of CMV in these syndromes is unclear, virus
replication may contribute to their natural history, and the role of
anti-CMV therapy in these conditions is currently being
investigated.
The available systemic anti-CMV drugs act by targeting the
viral DNA polymerase. These compounds effectively suppress
CMV replication, but their use is associated with considerable
toxicities to the bone marrow (Ganciclovir-GCV) and kidneys
(Foscarnet and Cidofovir) [8,9] and the emergence of drug-
resistant mutants during prolonged courses of therapy [9,10].
Thus, new compounds with low toxicity and ideally with a distinct
mechanism of CMV inhibition are needed for CMV therapy.
The artemisinin-derived monomer artesunate was originally
reported to inhibit CMV replication in vitro and in vivo [11,12].
Recently, we reported on two artemisinin-derived dimers with
significantly more potent activity against CMV replication in vitro
as compared to artemisinin-derived monomers [13]. Artemisinin
monomers are currently the drugs of choice for malaria therapy
[14]. In addition, both artemisinin monomers and dimers were
shown to possess anti-cancer activities [15–17]. The potent anti-
CMV activity of two artemisinin-derived dimers [13] prompted us
to evaluate a series of newly-synthesized artemisinin-derived
dimers. We report on the anti-CMV and anti-cancer activities of
the most potent compounds in this investigation.
Results
A comparison of anti-CMV activity of 17 artemisinin
derivatives
We previously reported on the anti-CMV activity of four
artemisinin monomers (artemisinin, artesunate, artemether, and
artefanlide) and two artemisinin-derived dimers (dimer primary
alcohol 606 and dimer sulfone 4-carbamate 832-4) [13]. We now
tested one new artemisinin-derived monomer and 10 additional
new artemisinin-derived dimers and compared their anti-CMV
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ated names of the 17 compounds and their molecular weights are
listed in Table 1. In this report, each compound is referred to by its
molecular weight. For example, compound 606 refers to the dimer
primary alcohol, and 832-4 refers to dimer sulfone 4-carbamate
(Table 1). Sulfone carbamate 551 is the monomeric version of
dimer sulfone carbamate 832-4. The chemical structure of dimer
sulfone 4-carbamate 832-4 prevents it from being catabolized into
monomer sulfone 4-carbamate 551. Compound 574, which is the
deoxy version of 606, was chosen for testing because the anti-
malarial and anti-cancer activities of artemisinins are at least
partially endoperoxide bridge-dependent [18,19].
The two previously tested artemisinin-derived dimers had
potent anti-CMV activity at concentrations of 1 mM or lower,
while the artemisinin-derived monomers achieved a similar degree
of CMV inhibition only at concentrations higher than 10 mM [13].
Based on these data, all new compounds were initially screened for
anti-CMV activities. The most active compounds were then tested
in detail for their anti-CMV activities. All dimers were initially
evaluated at concentrations of 1 mM, 0.3 mM, and 0.1 mM. The
deoxy dimer 574 and monomer sulfone carbamate 551 were
screened at 1 mM and 10 mM. At 1 mM, the dimers displayed
potent inhibition of late pp28 gene expression (which highly
correlates with plaque reduction) [20] measured by luciferase
activity, but the deoxy dimer 574 and monomer sulfone carbamate
551 did not (Fig. 1A). Several dimers were also effective at 0.3 mM,
but only two dimers, sulfone 4-carbamate 832-4 and diphenyl
phosphate 838, were highly inhibitory at 0.1 mM. Three structural
analogs of sulfone 832-4 were synthesized (832-3, 800-3 and 800-
4) varying the oxidation state and the position of the sulfur atom
on the aromatic ring (Fig. 1B). Though the meta-sulfide (800-3),
meta-sulfone (832-3), and para-sulfide (800-4) were active against
CMV replication at 0.3 mM, unlike para-sulfone 832-4 they were
not active at 0.1 mM (Fig. 1A). Therefore, the exact placement and
oxidation state of the sulfur atom contributes to its anti-CMV
activity.
We next screened for cellular toxicity of the dimers and
monomers using CellTiter-Glo Luminescent Cell Viability assay at
concentrations of 10 mM, 50 mM and 100 mM. For most dimers
(except 644 and 760), 50% cellular cytotoxicity (CC50) ranged
from 50 to 100 mM (Fig. 1C). Monomers overall displayed similar
cytotoxicity pattern, but were significantly more toxic than dimers
at 100 mM (P=0.03 by two-tailed t-test). Dimers 832-4 and 838
had the best selectivity index (SI), which is the ratio of CC50 to
EC50, and were therefore selected for further detailed analysis of
anti-CMV activity.
Structure-activity relationship and cell toxicity of dimers
832-4 and 838 and their parent dimers 760 and 606
A detailed comparison of anti-CMV activity and toxicity in non-
cancer primary HFF cells was next performed with the most
potent dimers, 832-4 and 838 (Fig. 2A). A dose-dependent increase
in anti-CMV activity was observed from 0.01 mMt o1mM for
both dimers 832-4 and 838 (Fig. 2B, Table 2). Cellular toxicities,
measured at 1 mM to 100 mM (Table 2), were not observed at
concentrations of complete CMV inhibition. The EC50,C C 50 and
SI are shown in Fig. 2B and Table 2. Dimers 832-4 and 838 had a
high SI, but 838 was the best compound. The parent alcohols
from which 832-4 and 838 were synthesized, 760 and 606,
respectively, were less effective than their derivatives in CMV
inhibition. For the 606-838 pair the difference in SI was 5-fold,
and for the 760-832-4 pair, 30-fold (Fig. 2A, 2B). Although the
dimer sulfone 4-carbamate 832-4 and the monomer sulfone 4-
carbamate 551 have identical sulfone 4-carbamate functional
groups (Fig. 2A), dimer 832-4 was at least 150 fold more effective
in CMV inhibition than monomer 551.
Inhibition of a GCV-resistant CMV strain by dimers 832-4
and 838
We evaluated the inhibition of a GCV-resistant strain (EC50 of
GCV=7.6 mM) by dimers 832-4 and 838 using a plaque
reduction assay. Dimers 832-4 and 838 were applied to infected
cells at a concentration of 0.1 mM; GCV was applied at 5 mM and
30 mM. Twenty one days after infection, cells were stained with
crystal violet and plaques were counted in each condition (Fig. 3).
Dimers 832-4 and 838 fully inhibited plaque formation at 0.1 mM,
while this strain showed an obvious resistance to GCV at 5 mM.
Slopes of the anti-CMV dose response curves of the
tested anti-CMV compounds
A classic description of dose-response relationships is the
median effect model based on mass action indicating that [21]:
fa~
1
1z(
EC50
D )
m
In this function, fa is the proportion of the inhibited fraction of
viruses, or the inhibition percentage, D is drug concentration, EC50
is the drug concentration that achieves 50% of the maximum
inhibitory effect and m is a slope parameter of the curve
mathematically. The effect of the slope parameter on anti-HIV
activity was recently evaluated, and proved to be a characteristic of
drug class and a crucial parameter dimension in the analysis of
antiviral activity [21].
We applied this model to our derivatives and calculated the slope
parameter of the most potent dimers (832-4 and 838), GCV, and
artemisinin-derived monomer artesunate (Table 2). Compared to
Table 1. List of artemisinin-derived monomers (first 5
compounds) and dimers evaluated for anti-CMV activity, and
their molecular weight (MW).
Compound MW
Artemisinin 282
Artemether 298
Artesunate 384
Artefanilide (ref 33) 433
Art-PrSO2Ph-4-CH2OC(O)NMe2 551
Deoxy-Dimer-isobu-OH 574
Dimer isobu-OH 606
Dimer isobu-COOH 620
5C Dimer OH 644
Dimer isobu-SO2Ph-4-CH2OH 760
Dimer isobu-SPh-3-CH2OC(O)NMe2 800-3
Dimer isobu-SPh-4-CH2OC(O)NMe2 800-4
5C Dimer OC(O)Ph-4-SO2Me 826
Dimer isobu-SO2Ph-4-CH2OC(O)NMe2 832-4
Dimer isobu-SO2Ph-3-CH2OC(O)NMe2 832-3
Dimer isobu-OP(O)(OPh)2 838
5C Dimer OC(O)CH2N(Boc)Bn 891
doi:10.1371/journal.pone.0024334.t001
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approximately 1, the m values of 832-4, 838, 760 and 606 were
around 4, an indication that these compounds are a highly potent
class of anti-CMV compounds.
Inhibition of cancer cell growth by dimers 832-4 and 838
Artemisinin-derived monomers and several dimers have been
reported to inhibit the growth of cancer cell-lines [16,17]. Four
dimers (832-4, 838, 760 and 606), two monomers (artesunate and
artefanilide) and GCV were applied to three cancer cell lines:
HeLa (cervical adenocarcinoma), HCT116 (colorectal carcinoma)
and 1205Lu (melanoma) at concentrations ranging from 0.01 mM
to 1 mM. MTT assay was performed 72 hr after treatment and
CC50 of each compound in each cancer cell line was calculated
(table 3). The CC50 of each compound in cancer cells was
compared to the CC50 in non-cancer primary HFF cells. All
dimers were significantly more active than monomers in inhibiting
the growth of cancer cell lines. For example, the dimer 838 was at
least 200-fold more potent in inhibiting growth of HCT116 and
1205Lu cells and 37-fold more potent in inhibiting growth of
HeLa cells, as compared to artesunate, the most potent monomer
in this assay. A qualitative correlation was observed between the
anti-CMV activity and the anti-cancer activity among the four
dimers (838, 832-4, 606 and 760); dimer 838, the most potent of
all tested dimers against CMV replication, also had the strongest
effect on growth inhibition of cancer cells.
Discussion
We report here on the anti-CMV activity of ten new
artemisinin-derived dimers, one deoxy dimer and one new
artemisinin monomer, and the identification of the most potent
anti-CMV dimer. The enhanced anti-CMV activity of dimers as
compared to monomers was not a result of increased cytotoxcity
but rather a specific anti-CMV activity. The two most highly
potent dimers were effective in inhibition of the laboratory-
adapted Towne strain as well as a GCV-resistant strain. They
were also shown to have the strongest inhibitory effect on the
growth of cancer cell lines.
All dimers exhibited potent CMV inhibition at 1 mM. However,
only two compounds (832-4 and 838) could be selected as highly
potent anti-CMV agents based on their high CMV inhibition at
0.1 mM and their low cytotoxicity. At this concentration, the other
dimers had either no inhibition or at most 40% inhibition of
luciferase expression, while GCV had no inhibition at all.
Artemisinin derivatives were initially developed as anti-malarial
drugs, but later were also found to have additional pharmacolog-
ical activities such as growth inhibition of cancer cells and
inhibition of CMV replication [12,13,22–25]. Whether or not
Figure 1. Anti-CMV activity and cytotoxicity of artemsinin-
derived compounds. A: Relative luciferase activity of artemsinin-
derived dimers (left), deoxy dimer 574, and artemisinin monomers
(right). Infected and treated HFFs were collected 72 hpi and washed
once with PBS. The lysates were assayed for luciferase activity using the
Luciferase Assay Kit (Promega, Madison, WI). B. Chemical structure of
analogs of dimer sulfone 4-carbamate 832-4. Depicted are two sulfide
carbamate analogs (800-3 and 800-4) and one sulfone 3-carbamate
analog (832-3) of sulfone 4-carbamate 832-4. C: Cytotoxicity of ten
artemisinin-dimers and five artemisinin-monomers in HFF. HFFs treated
with dimers/monomers at the indicated concentrations were collected
at 72 and washed once with PBS. The lysates were assayed for cell
viability using CellTiter-Glo Luminescent Cell Viability Assay Kit on
GloMaxH-Multi+ Detection System (Promega) according to manufac-
turer’s instructions.
doi:10.1371/journal.pone.0024334.g001
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mechanism, the endoperoxide bridge appears to be critical in all
pharmacological activities of artemisinin derivatives.
As a generalized observation, the dimers were significantly more
potent than the monomers in CMV inhibition. Using the EC50
values, dimer 838 was 165-fold more potent than artesunate in anti-
CMV activity and its SI was 134-fold higher compared to
artesunate. In support of this finding, the model of dose response
slope parameter which was recently used to characterize the
activities of anti-HIV compounds [21] revealed that dimers had a
much higher slope than monomers. Generally, a higher slope
correlates with a more vigorous anti-viral activity. This could result
either from very high affinity of drug binding to a single ligand or
from cooperative effect of multiple ligands with similar affinity.
Several anti-cancer agents (such as kinase inhibitors) have been
shown to inhibit CMV replication, but in general, the concentra-
tions required to achieve CMV inhibition were toxic to cells and
prohibited their use as anti-viral candidates [26]. Interestingly,
Sorafenib, a multi-kinase inhibitor, appears to inhibit CMV
replication without associated cellular toxicity [27]. The dimers
reported here prevented growth of cancer cell-lines and were
potent inhibitors of CMV replication without apparent cellular
toxicities. Therefore, they may provide a new class of anti-CMV
agents, with a distinct mechanism of action. Similar to the anti-
CMV activity, dimers were also more effective than monomers in
inhibition of cancer cells. Future studies may reveal whether the
dual anti-CMV and anti-cancer activities of dimers result from a
shared mechanism of action. We and others have shown that
inhibition of CMV replication with artemisinin derivatives appears
early during the replication cycle and involves a mechanism which
is different from the DNA polymerase inhibitors [28,29]. The anti-
cancer activities of artemisinins have been postulated to involve
cell cycle arrest, apoptosis, and/or angiogenesis [30], processes
that are also affected by specific CMV genes, mostly immediate
early genes. Future studies will address the mechanism of CMV
inhibition by artemisinin-derived dimers and their potential
overlap with oncogenic signaling events.
In conclusion, we have shown that: 1). Dimers are highly active
against CMV replication, and dimer diphenyl phosphate 838 is
the most potent in CMV inhibition. 2). The dose response slope
parameter of dimers is significantly higher than that of artemisinin
monomers and GCV, a possible indication that dimers are a
distinct class of anti-CMV compounds. 3) Dimers are more potent
inhibitors than monomers in both cancer cell lines and in CMV.
Materials and Methods
Compounds
Ganciclovir (GCV) was obtained from Roche, USA. All
artemisinin derivatives used in this study were synthesized at
Table 2. EC50,C C 50, selectivity index (SI) and m (slope) for the
most potent dimers, artesunate and GCV.
Compounds EC50 (mM) CC50 (mM) SI Slope
832-4 0.0760.004 57.562.9 909.8681 3.660.7
838 0.0460.003 55.862.8 14726127 3.960.2
760 0.1460.008 4.960.2 34.562 4.061.0
606 0.1660.008 48.162.6 292621 3.560.7
artesunate 6.660.4 71.7641 1 60.9 1.160.02
GCV 2.760.1 247633.4 96614 1.360.06
Dimer alcohol 760 is the parent compound of 832-4 dimer sulfone carbamate.
Dimer alcohol 606 is the parent compound of 838 dimer diphenyl phosphate.
doi:10.1371/journal.pone.0024334.t002
Figure 2. Chemical structure and anti-CMV activity of the two
most potent artemisinin-derived dimers and their correspond-
ing parent compounds. A: Chemical structures of the two most
potent artemisinin-derived dimers 838 and 832-4 and their correspond-
ing parent alcohols 606 and 760. Monomer 551 is depicted on the left
of dimer 832-4. The sulfone benzylic dimethyl carbamate unit is the
same in monomer 551 as in dimer 832-4. Therefore, the enhanced anti-
CMV activity of the dimer 832-4 over monomer 551 is not due to any
difference in the sulfone carbamate portion of the molecule. B: Detailed
anti-CMV activity of dimers 832-4 and 838, and their respective parent
compounds 760 and 606. CMV-infected HFF were treated with dimers
832-4 and 838 at the indicated concentrations. 72 hpi luciferase activity
was determined in the lysates of infected cells. Luciferase values
represent the mean and SD of data derived from at least four
independent experiments performed in triplicates. The curve fitting
toolbox, Matlab software (v7.5), Mathworks (Natick, MA) was used to
determine EC50 values using a four-parameter logistic regression.
doi:10.1371/journal.pone.0024334.g002
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sulfide 3-carbamate (800-3) and dimer sulfide 4-carbamate (800-4)
as well as dimer sulfone 3-carbamate (832-3) were synthesized as
described in Materials S1. Artemisinin-derived monomers and
dimers were dissolved in dimethyl sulfoxide (DMSO) and stocks of
10 mM were stored in 280uC. Synthetic compounds were at least
98% pure based on proton NMR spectroscopy. The DMSO itself
was tested in CMV-infected cells, and it did not have any anti-viral
activity [13].
Viruses
The pp28-luciferase Towne strain was constructed as previously
described [20]. Briefly, the recombinant virus, which expresses
luciferase under the control of UL99 (pp28) late promoter was
generated by insertion of the reporter gene between the US9 and
US10 open reading frames (ORFs) in the Towne genome. The
expression of pp28 –luciferase is strongly activated 48–72 hours
post infection (hpi) and is almost completely inhibited in the
presence of DNA polymerase inhibitors such as GCV and
foscarnet [20]. We have recently reported that the pp28-luciferase
reporter system is sensitive, reproducible and highly correlates
with plaque reduction [20]. The ganciclovir (GCV)-resistant strain
was obtained from a patient with CMV disease. It has a UL97
mutation (H520Q) and an EC50 of 7.6 mM for GCV. This clinical
isolate was provided by the clinical virology laboratory with no
identifiers that can link to a specific subject. The Johns Hopkins
Office of Human Subject Research Institutional Review Board
determined that this research qualified for an exemption.
Cell Culture, Virus Infection and Anti-viral assays
Human Foreskin Fibroblasts (HFF) passage 12–16 (ATCC,
CRL-2088
TM) were grown in Dulbecco’s Modified Eagle Medium
(DMEM) containing 10% fetal bovine serum (Gibco, Carlsbad,
CA) in a 5% CO2 incubator at 37uC and used for infections with
pp28-luciferase Towne CMV or the GCV-resistant strain. One
day prior to infection with the pp28-luciferase, 4610
4 HFF cells
were seeded on each well of 24-well tissue culture plates. Infection
was carried out at multiplicity of infection of 1 PFU/cell
(MOI=1). Following 90 minute adsorption, media containing
virus was removed and replaced by DMEM with 4% fetal bovine
serum (Gibco, Carlsbad, CA) containing anti-viral compounds.
The concentration of each compound was calculated and adjusted
by volume such that it was constant throughout the experiment.
Infected and treated HFF cells were collected 72 hpi and
washed once with PBS. The lysates were assayed for luciferase and
cell viability using a Luciferase Assay Kit (Promega, Madison, WI)
and CellTiter-Glo Luminescent Cell Viability Assay Kit, respec-
tively, on GloMaxH-Multi+ Detection System (Promega) accord-
ing to manufacturer’s instructions.
Figure 3. Activity of 832-4, 838 and GCV against a GCV-resistant CMV strain. A plaque reduction assay was used to quantify the inhibition
of the GCV-resistant CMV. CMV-infected HFF were treated with 832-4, 838 and GCV at the indicated concentrations. Plaques were counted 21 days
post infection.
doi:10.1371/journal.pone.0024334.g003
Table 3. CC50 in three types of cancer cell lines: HeLa, 1205Lu,
HCT116, and in non-cancer primary HFF cells.
CC50 (mM)
Compound HeLa 1205Lu HCT116 HFF
832-4 0.2760.03 0.1360.007 0.0760.006 57.562.9
838 0.1960.08 0.0660.002 0.0460.005 55.862.8
760 0.5660.18 0.160.006 0.0760.005 4.960.2
606 1.0660.2 4.960.04 0.160.001 48.162.6
Artesunate 7.160.4 4262.4 11.360.6 71.764
Artefanilide .50 .50 4067.9 44.963.4
GCV .50 .50 .50 247633.4
doi:10.1371/journal.pone.0024334.t003
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137
TM) were grown in DMEM containing 10% fetal bovine
serum. One day prior to infection, 3610
5 cells were seeded on
each well of 12-well tissue culture plates. GCV-resistant CMV was
diluted in DMEM to a desired concentration which gave around
100 plaques per well and added to each well in duplicates. Plates
were incubated for 90 minutes with shaking every 10 min;
thereafter drugs were added and a methylcellulose overlay applied
to each well. After incubation for 21 days, cells were stained with
crystal violet and plaques were counted under microscope at 406
magnification.
Anti-Cancer Cells Assay
HeLa (Human Cervical Adenocarcinoma), HCT116 (Human
Colorectal Carcinoma) and 1205Lu (Human Melanoma) cells (all
from ATCC) were maintained in DMEM containing 10% fetal
bovine serum. 12–16 hours prior to drug treatment, 3610
3 to
5610
3 cells were seeded on each well of 96-well tissue culture
plates. Drugs were diluted in DMEM containing 10% fetal bovine
serum and applied to the cells. 72 hours after drug treatment,
20 ml of MTT solution (5 mg/ml in PBS) was added into each
well, followed by shaking the plates at 150 rpm for 5 minutes and
an incubation of 4 hours (37uC, 5% CO2). Media was removed,
plates dried and each well was resuspended in 100 ml MTT
formazan/DMSO. The absorbance of each well was recorded at
560 nm on GloMaxH-Multi+ Detection System (Promega).
Supporting Information
Materials S1 1) Synthesis of Dimer Sulfide 3-Carbamate 800-
3. 2) Synthesis of Dimer Sulfone 3-Carbamate 832-3. 3) Synthesis
of Dimer Sulfide 4-Carbamate 800-4. 4) Synthesis of deoxy-
artemisinin alcohol 574. 5) Synthesis of Monomer Sulfone
Benzylic Dimethyl Carbamate 551.
(DOC)
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